• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure enrolls 1st patient in Phase III brain metastases trial

October 12, 2016 By Sarah Faulkner

Novocure enrolls 1st patient in phase III brain metastases trialNovocure (NSDQ:NVCR) said that the 1st patient has been enrolled in a Phase III pivotal trial of its tumor-treating field technology in combination with radiosurgery to treat brain metastases from non-small-cell lung cancer.

The St. Helier, N.J.-based company’s tumor treating fields (TTFields) are low-intensity, intermediate-frequency, alternating electric fields designed to disrupt cell division within cancer cells. Novocure’s commercial product, Optune, is indicated in the U.S. as a therapy in combination with temozolomide to treat gliobastoma.

Metis is the company’s 1st Phase III trial of TTFields for a cancer other than glioblastoma. The study, slated to enroll 270 patients with 1 to 10 brain mestastases, will compare patients who, following radiosurgery, receive TTFields and supportive care to those who receive only supportive care.

“We are excited to start the Metis trial and are working to diligently enroll patients,” chief science officer Dr. Eilon Kirson said in prepared remarks. “[Non-small cell lung cancer] patients with brain metastases suffer not only from their primary disease in the lungs, but also from the risk of neurocognitive deterioration due to the recurrence of brain metastases or neurotoxic treatments. We believe TTFields has the potential be an effective treatment option to prevent the appearance of new brain metastases without causing additional neurotoxicity.”

“We are happy to enroll the first patient in the Metis trial,” added Dr. Nicholas Blondin of Associated Neurologists of Southern Connecticut. “Brain metastases patients deserve more treatment options, and this trial will assess the efficacy and safety of TTFields in the treatment of brain metastases.”

 

 

Last month, Novocure touted a long-term analysis of data from a pivotal study of the Optune-temozolomide combination treatment in newly-formed glioblastomas. The company also claims positive results both in vitro and in vivo for the combination of Optune and paclitaxel in treating ovarian cancer.

Novocure won pre-market approval from the FDA for the Optune-temozolomide combination for glioblastoma in July.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS